Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by (68) Ga-PSMA-positron emission tomography/computerized tomography.

The first evaluation of pelvic extended lymph node dissection (pLND) in oligometastatic prostate cancer (PCa) detected by (68) Ga-PSMA PET/CT.

Retrospective analysis of 35 PCa patients underwent (68) Ga-PSMA PET/CT affected by biochemical recurrence (BCR) after curative treatment (n = 23) or before primary therapy of high-risk PCa (n = 12).

We performed pLND associated with pathologic imaging in 17 men with nodal oligometastatic PCa.

Indicative lesions for PCa in PET/CT were detected in 91. 4% (32 of 35) of patients. Nodal, bone, visceral (pulmonary), and within the prostate suspected disease were detected in 72% (23 of 32), 16% (5 of 32), 6% (2 of 32), and 47% (15 of 32) of patients, respectively. Median serum PSA in patients with pathological radiotracer uptake in recurrent and high-risk PCa patients was 2. 9 ng/ml (range 0. 18-30) and 19. 5 ng/ml (range 6-90), respectively. The median number of removed lymph nodes with pLND in recurrent and high-risk PCa was 10 (range 4-17) and 12 (range 8-29) per patient and the median number of positive lymph nodes was 1 (range 1-2) and 3 (2-3) per patient, respectively. In total, two false positive and one false-negative lymph node were found. Diagnostic accuracies per nodal lesion in total of 213 removed nodes: sensitivity, 94%; specificity, 99%; positive predictive value (PPV), 89%, and negative predictive value (NPV), 99. 5%. After pLND, 53% (9 of 17) of patients received androgen deprivation therapy and/or radiation therapy and hormonal therapy, while 47% (8 of 17) of patients remained free of any post-surgery therapy. Follow-up PSA remained less than 0. 2 ng/ml in 82% (14 of 17) of patients. After pLND, immediate BCR (PSA never measured less than 0. 2 ng/ml) in 18% (3 of 17) of patients was recorded.

This represents the first study of pLND in the setting of nodal oligometastatic PCa detected by (68) Ga-PSMA PET/CT. The use of (68) Ga-PSMA PET/CT could be to improve the accuracy for the detection of nodal micrometastases. These promising findings need validation in larger studies. Prostate © 2015 Wiley Periodicals, Inc.

The Prostate. 2015 Sep 10 [Epub ahead of print]

S Hijazi, B Meller, C Leitsmann, A Strauss, J Meller, C O Ritter, J Lotz, H-U Schildhaus, L Trojan, C O Sahlmann

Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany. , Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. , Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. , Institute of Pathology, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe